|
| Reference, country | Setting and population (age group, years) | Drug administered in MDA programme | MDA coverage or compliance (%) |
|
| [14], Mali | Inhabitants of villages (≥2) | Albendazole and ivermectin | >67 |
| [15], American Samoa | Household members in villages (≥2) | Diethylcarbamazine and albendazole | (56, 19–71) |
| [16], Egypt | Community members (>5) | Diethylcarbamazine and albendazole | >85 |
| [17], Sierra Leone | Community members (>5) | Albendazole and ivermectin | 82.5–88.5 |
| [18], Sierra Leone | Community members (>5) | Albendazole and ivermectin | 75.9–79.6 |
| [19], Nigeria | Community members (>5) | Albendazole and ivermectin | 72.2–96 |
| [20], Egypt | Village surveys (≥2) | Diethylcarbamazine and albendazole | >†80 |
| [21], India | Community members, — | Diethylcarbamazine-medicated salt | 100 |
| [22], Tanzania | Students (≥1) | Albendazole and ivermectin | 62.1–94.8 |
| [23], Tanzania | Standard 1 pupils (7.5–8.1) | Albendazole and ivermectin | 87.7–94.5 |
| [24], Tanzania | Students and community members (≥1 and ≥10) | Albendazole and ivermectin | 75–98.7 |
| [25], Tanzania | Students and community members (≥10) | Albendazole and ivermectin | 46–56 |
| [26], Indonesia | Residents in villages (≥5) | Diethylcarbamazine and albendazole | †70.1–89.8 |
| [27], Papua New Guinea | Residents of rural villages (≥2) | Diethylcarbamazine and albendazole | †72.9 |
|
